Vestnik dermatologii i venerologiiVestnik dermatologii i venerologiiВестник дерматологии и венерологии0042-46092313-6294Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov126910.25208/vdv1269REVIEWSОБЗОР ЛИТЕРАТУРЫReview ArticleGenetic markers for psoriatic arthritis among patients with psoriasis. Part II: HLA genesГенетические маркеры развития поражения суставов у больных псориазом. Часть II: Гены системы HLAhttps://orcid.org/0000-0002-7625-05038771-4990KubanovA. A.КубановА. А.
Russian Federation

MD, Dr. Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences

д.м.н., профессор, член-корреспондент РАН

alex@cnikvi.ruhttps://orcid.org/0000-0002-9688-27273385-4723ChikinV. V.ЧикинВ. В.
Russian Federation

MD, Dr. Sci. (Med.)

д.м.н

chikin@cnikvi.ruhttps://orcid.org/0000-0003-3805-84893604-6491KaramovaA. E.КарамоваА. Э.
Russian Federation

Cand. Sci. (Med.)

к.м.н.

karamova@cnikvi.ruhttps://orcid.org/0000-0002-2553-04849552-7850ZnamenskayaL. F.ЗнаменскаяЛ. Ф.
Russian Federation

MD, Dr. Sci. (Med.)

д.м.н

znaml@cnikvi.ruhttps://orcid.org/0000-0003-3778-47453308-3330ArtamonovaO. G.АртамоноваО. Г.
Russian Federation

junior research associate

младший научный сотрудник

artamonova_olga@list.ruhttps://orcid.org/0000-0002-1104-76948261-6561VerbenkoD. A.ВербенкоД. А.
Russian Federation

MD, Cand. Sci. (Med.)

к.м.н.

verbenko@gmail.comState Research Center of Dermatovenereology and CosmetologyГосударственный научный центр дерматовенерологии и косметологии231220219756171808202128102021Copyright ©; 2021, Kubanov A.A., Chikin V.V., Karamova A.E., Znamenskaya L.F., Artamonova O.G., Verbenko D.A.Copyright ©; 2021, Кубанов А.А., Чикин В.В., Карамова А.Э., Знаменская Л.Ф., Артамонова О.Г., Вербенко Д.А.2021Kubanov A.A., Chikin V.V., Karamova A.E., Znamenskaya L.F., Artamonova O.G., Verbenko D.A.Кубанов А.А., Чикин В.В., Карамова А.Э., Знаменская Л.Ф., Артамонова О.Г., Вербенко Д.А.https://creativecommons.org/licenses/by/4.0https://vestnikdv.ru/jour/article/view/1269

Psoriatic arthritis often leads to the development of severe outcomes — ankylosis, deformities of the affected joints with severe impairment of their functions and disability. Early identification of patients with psoriasis with an increased risk of developing psoriatic arthritis for the purpose of its timely diagnosis and early initiation of therapy can prevent the development of severe disease outcomes. It is believed that the genes of the HLA system make the greatest individual genetic contribution to the formation of a predisposition to hereditary diseases with polygenic inheritance. The literature review considers the polymorphisms of the genes of the HLA system, associated with the development of psoriatic arthritis, in patients with psoriasis. The HLA alleles that contribute to the development of psoriatic arthritis and its individual forms have been identified. HLA alleles have been identified, which have a protective effect against the development of psoriatic arthritis.

Псориаз артропатический (псориатический артрит) часто приводит к развитию тяжелых исходов — анкилозов, деформаций пораженных суставов с выраженным нарушением их функций и инвалидности. Раннее выявление больных псориазом с повышенным риском развития псориатического артрита с целью его своевременной диагностики и раннего начала терапии может предотвратить развитие тяжелых исходов болезни. Считается, что наибольший индивидуальный генетический вклад в формирование предрасположенности к наследственным заболеваниям с полигенным наследованием вносят гены системы HLA. В обзоре литературы рассмотрены полиморфизмы генов системы HLA, ассоциированные с развитием псориатического артрита у больных псориазом. Определены аллели HLA, способствующие развитию псориатического артрита и его отдельных форм. Выделены аллели HLA, которые обладают протективным эффектом в отношении развития псориатического артрита.

psoriatic arthritisHLA genesHLA-B*27псориатический артритгены системы HLAHLA-B*27the work was done through financing at the place of work of the authorsработа выполнена за счет финансирования по месту работы авторовBlauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379–390. doi: 10.1007/s12016-018-8702-3Лила А.М., Насонов Е.Л., Коротаева Т.В. Псориатический артрит: патогенетические особенности и инновационные методы терапии. Научно-практическая ревматология. 2018;56(6):685–686 [Lila AM, Nasonov EL, Korotaeva TV. Psoriatic arthritis: pathogenetic features and innovative therapies. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(6):685–691 (In Russ.)] doi: 10.14412/1995-4484-2018-685-691Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018;391(10136):2273–2284. doi: 10.1016/S0140-6736(18)30830-4Taams LS, Steel KJA, Srenathan U, Burns LA, Kirkham BW. IL-17 in the immunopathogenesis of spondyloarthritis. Nat Rev Rheumatol. 2018;14(8):453–466. doi: 10.1038/s41584-018-0044-2Szczerkowska-Dobosz A, Krasowska D, Bartosińska J, Stawczyk-Macieja M, Walczak A, Owczarczyk-Saczonek A, et al. Pathogenesis of psoriasis in the “omic” era. Part IV. Epidemiology, genetics, immunopathogenesis, clinical manifestation and treatment of psoriatic arthritis. Postepy Dermatol Alergol. 2020;37(5):625–634.doi: 10.5114/ada.2020.100478Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447(7145):661–678. doi: 10.1038/nature05911Fiorillo MT, Paladini F, Tedeschi V, Sorrentino R. HLA Class I or class II and disease association: Catch the difference if you can. Front Immunol. 2017;8:1475. doi: 10.3389/fimmu.2017.01475Busch R, Kollnberger S, Mellins ED. HLA associations in inflammatory arthritis: emerging mechanisms and clinical implications. Nat Rev Rheumatol. 2019;15(6):364–381. doi: 10.1038/s41584-019-0219-5Liu B, Shao Y, Fu R. Current research status of HLA in immune-related diseases. Immun Inflamm Dis. 2021;9(2):340–350.doi: 10.1002/iid3.416Neefjes J, Jongsma ML, Paul P, Bakke O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol. 2011;11(12):823–836. doi: 10.1038/nri3084Trowsdale J, Knight JC. Major histocompatibility complex genomics and human disease. Annu Rev Genomics Hum Genet. 2013;14:301–323. doi: 10.1146/annurev-genom-091212-153455Robinson J, Barker DJ, Georgiou X, Cooper MA, Flicek P, Marsh SGE. IPD-IMGT/HLA Database. Nucleic Acids Res. 2020;48(D1):D948-D955. doi: 10.1093/nar/gkz950Busch R, Kollnberger S, Mellins ED. HLA associations in inflammatory arthritis: emerging mechanisms and clinical implications. Nat Rev Rheumatol. 2019;15(6):364–381. doi: 10.1038/s41584-019-0219-5Marsh SG, Albert ED, Bodmer WF, Bontrop RE, Dupont B, Erlich HA, et al. Nomenclature for factors of the HLA system, 2010. Tissue Antigens. 2010;75(4):291–455. doi: 10.1111/j.1399-0039.2010.01466.xWieczorek M, Abualrous ET, Sticht J, Álvaro-Benito M, Stolzenberg S, Noé F, Freund C. Major Histocompatibility Complex (MHC) class I and MHC class II proteins: Conformational plasticity in antigen presentation. Front Immunol. 2017;8:292. doi: 10.3389/fimmu.2017.00292Yewdell JW, Bennink JR. The binary logic of antigen processing and presentation to T cells. Cell. 1990;62(2):203–206.doi: 10.1016/0092-8674(90)90356-jWilliamson L, Dockerty JL, Dalbeth N, McNally E, Ostlere S, Wordsworth BP. Clinical assessment of sacroiliitis and HLA-B27 are poor predictors of sacroiliitis diagnosed by magnetic resonance imaging in psoriatic arthritis. Rheumatology (Oxford). 2004;43(1):85–88.doi: 10.1093/rheumatology/keg475Lopez-Larrea C, Torre Alonso JC, Rodriguez Perez A, Coto E. HLA antigens in psoriatic arthritis subtypes of a Spanish population. Ann Rheum Dis. 1990;49(5):318–319. doi: 10.1136/ard.49.5.318Liao HT, Lin KC, Chang YT, Chen CH, Liang TH, Chen WS, et al. Human leukocyte antigen and clinical and demographic characteristics in psoriatic arthritis and psoriasis in Chinese patients. J Rheumatol. 2008;35(5):891–895.Winchester R, Minevich G, Steshenko V, Kirby B, Kane D, Greenberg DA, et al. HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype. Arthritis Rheum. 2012;64(4):1134–1144. doi: 10.1002/art.33415.Бадокин В.В., Трошкина И.А., Гусева И.А. Значение генетической компоненты в клинической презентации псориатического артрита. Доктор.Ру. 2012;2(70):44–49 [Badokin VV, Troshkina IA, Guseva IA. Psoriatic arthritis: Role of genetic component in disease’s clinical manifestation. Doktor.ru. 2012;2(70):44–49 (In Russ.)]Elkayam O, Segal R, Caspi D. Human leukocyte antigen distribution in Israeli patients with psoriatic arthritis. Rheumatol Int. 2004;24(2):93–97. doi: 10.1007/s00296-003-0325-0Chandran V, Tolusso D, Cook R, Gladman D. Risk factors for axial inflammatory arthritis in patients with psoriatic arthritis. J Rheumatol. 2010;37(4):809–815. doi: 10.3899/jrheum.091059Suarez-Almazor ME, Russell AS. Sacroiliitis in psoriasis: relationship to peripheral arthritis and HLA-B27. J Rheumatol. 1990;17(6):804–808Queiro R, Sarasqueta C, Belzunegui J, Gonzalez C, Figueroa M, Torre-Alonso JC. Psoriatic spondyloarthropathy: a comparative study between HLA-B27 positive and HLA-B27 negative disease. Semin Arthritis Rheum. 2002;31(6):413–418. doi: 10.1053/sarh.2002.33470Mazzanti G, Coloni L, Desabbata G, Paladini G. Is HLA B27 a true marker of axial involvement in psoriatic arthropathy? Acta Derm Venereol Suppl (Stockh). 1994;186:71–72.Winchester R, Giles J, Jadon D, Haroon M, McHugh N, FitzGerald O. Implications of the diversity of class I HLA associations in psoriatic arthritis. Clin Immunol. 2016;172:29–33. doi: 10.1016/j.clim.2016.07.019Haroon M, Winchester R, Giles JT, Heffernan E, FitzGerald O. Clinical and genetic associations of radiographic sacroiliitis and its different patterns in psoriatic arthritis. Clin Exp Rheumatol. 2017;35(2):270–276.Haroon M, Winchester R, Giles JT, Heffernan E, FitzGerald O. Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype. Ann Rheum Dis. 2016;75(1):155–162. doi: 10.1136/annrheumdis-2014-205461Polachek A, Cook R, Chandran V, Abji F, Gladman D, Eder L. The association between HLA genetic susceptibility markers and sonographic enthesitis in psoriatic arthritis. Arthritis Rheumatol. 2018;70(5):756–762. doi: 10.1002/art.40423Eastmond CJ. Psoriatic arthritis: genetics and HLA antigens. Baillieres Clin Rheumatol. 1994;8(2):263–276. doi: 10.1016/s0950-3579(94)80018-9Gladman DD, Farewell VT, Kopciuk KA, Cook RJ. HLA markers and progression in psoriatic arthritis. J Rheumatol. 1998;25(4):730–733.Trabace S, Cappellacci S, Ciccarone P, Liaskos S, Polito R, Zorzin L. Psoriatic arthritis: a clinical, radiological and genetic study of 58 Italian patients. Acta Derm Venereol Suppl (Stockh). 1994;186:69–70.Espinoza LR, Vasey FB, Oh JH, Wilkinson R, Osterland CK. Association between HLA-BW38 and peripheral psoriatic arthritis. Arthritis Rheum. 1978;21(1):72–75. doi: 10.1002/art.1780210112Murray C, Mann DL, Gerber LN, Barth W, Perlmann S, Decker JL, et al. Histocompatibility alloantigens in psoriasis and psoriatic arthritis: evidence for the influence of multiple genes in the major histocompatibility complex. J Clin Invest. 1980;66(4):670–675. doi: 10.1172/JCI109903Matsumura M, Fremont DH, Peterson PA, Wilson IA. Emerging principles for the recognition of peptide antigens by MHC class I molecules. Science. 1992;257(5072):927–934. doi: 10.1126/science.1323878Bouvier M, Wiley DC. Importance of peptide amino and carboxyl termini to the stability of MHC class I molecules. Science. 1994;265(5170):398–402. doi: 10.1126/science.8023162Zacharias M, Springer S. Conformational flexibility of the MHC class I alpha1-alpha2 domain in peptide bound and free states: a molecular dynamics simulation study. Biophys J. 2004;87(4):2203–2214. doi: 10.1529/ biophysj.104.044743Saini SK, Ostermeir K, Ramnarayan VR, Schuster H, Zacharias M, Springer S. Dipeptides promote folding and peptide binding of MHC class I molecules. Proc Natl Acad Sci USA. 2013;110(38):15383–15388. doi: 10.1073/pnas.1308672110Abualrous ET, Saini SK, Ramnarayan VR, Ilca FT, Zacharias M, Springer S. The carboxy terminus of the ligand peptide determines the stability of the MHC class I molecule H-2Kb: a combined molecular dynamics and experimental study. PLoS One. 2015;10:e0135421. doi: 10.1371/journal. pone.0135421Sarkizova S, Klaeger S, Le PM, Li LW, Oliveira G, Keshishian H, Hartigan CR, et al. A large peptidome dataset improves HLA lass I epitope prediction across most of the human population. Nat Biotechnol. 2020;38(2):199–209. doi: 10.1038/s41587-019-0322-9Rammensee HG, Friede T, Stevanoviic S. MHC ligands and peptide motifs: first listing. Immunogenetics. 1995;41(4):178–228. doi: 10.1007/BF00172063Taurog JD. The mystery of HLA-B27: if it isn't one thing, it's another. Arthritis Rheum. 2007;56(8):2478–2481. doi: 10.1002/art.22807.Khan MA, Mathieu A, Sorrentino R, Akkoc N. The pathogenetic role of HLA-B27 and its subtypes. Autoimmun Rev. 2007;6(3):183–189. doi: 10.1016/j.autrev.2006.11.003D'Amato M, Fiorillo MT, Carcassi C, Mathieu A, Zuccarelli A, Bitti PP, et al. Relevance of residue 116 of HLA-B27 in determining susceptibility to ankylosing spondylitis. Eur J Immunol. 1995;25(11):3199–3201. doi: 10.1002/eji.1830251133Madden DR. The three-dimensional structure of peptide-MHC complexes. Annu Rev Immunol. 1995;13:587–622. doi: 10.1146/annurev.iy.13.040195.003103Ziegler A, Loll B, Misselwitz R, Uchanska-Ziegler B. Implications of structural and thermodynamic studies of HLA-B27 subtypes exhibiting differential association with ankylosing spondylitis. Adv Exp Med Biol. 2009;649:177–195. doi: 10.1007/978-1-4419-0298-6_13Fabian H, Huser H, Loll B, Ziegler A, Naumann D, Uchanska-Ziegler B. HLA-B27 heavy chains distinguished by a micropolymorphism exhibit differential flexibility. Arthritis Rheum. 2010;62(4):978–987. doi: 10.1002/art.27316Crux NB, Elahi S. Human leukocyte antigen (HLA) and immune regulation: how do classical and nonclassical HLA alleles modulate immune response to human immunodeficiency virus and hepatitis C virus infections? Front Immunol. 2017;8:832. doi: 10.3389/fimmu.2017.00832Lenart I, Guiliano DB, Burn G, Campbell EC, Morley KD, Fussell H, et al. The MHC class I heavy chain structurally conserved cysteines 101 and 164 participate in HLA-B27 dimer formation. Antioxid. Redox Signal. 2012;16(1):33–43. doi: 10.1089/ars.2010.3693Bird LA, Peh CA, Kollnberger S, Elliott T, McMichael AJ, Bowness P. Lymphoblastoid cells express HLA-B27 homodimers both intracellularly and at the cell surface following endosomal recycling. Eur J Immunol. 2003;33(3):748–759. doi: 10.1002/eji.200323678Kollnberger S, Bird L, Sun MY, Retiere C, Braud VM, McMichael A, Bowness P. Cell-surface expression and immune receptor recognition of HLA-B27 homodimers. Arthritis Rheum. 2002;46(11):2972–2982. doi: 10.1002/art.10605MacLean L, Macey M, Lowdell M, Badakere S, Whelan M, Perrett D, Archer J. Sulphydryl reactivity of the HLA-B27 epitope: accessibility of the free cysteine studied by flow cytometry. Ann Rheum Dis. 1992;51(4):456–460. doi: 10.1136/ard.51.4.456Navid F, Colbert RA. Causes and consequences of endoplasmic reticulum stress in rheumatic disease. Nat Rev Rheumatol. 2017;13(1):25–40. doi: 10.1038/nrrheum.2016.192Powis SJ, Colbert RA. Editorial: HLA-B27: The story continues to unfold. Arthritis Rheumatol. 2016;68(5):1057–1059. doi: 10.1002/art.39566Dong W, Zhang Y, Yan M, Liu H, Chen Z, Zhu P. Upregulation of 78-kDa glucose-regulated protein in macrophages in peripheral joints of active ankylosing spondylitis. Scand J Rheumatol. 2008;37(6):427–434. doi: 10.1080/03009740802213310Guiliano DB, North H, Panayoitou E, Campbell EC, McHugh K, Cooke FG, et al. Polymorphisms in the F pocket of HLA-B27 subtypes strongly affect assembly, chaperone interactions, and heavy-chain misfolding. Arthritis Rheumatol. 2017;69(3):610–621. doi: 10.1002/art.39948Jeanty C, Sourisce A, Noteuil A, Jah N, Wielgosik A, Fert I, Breban M, et al. HLA-B27 subtype oligomerization and intracellular accumulation patterns correlate with predisposition to spondyloarthritis. Arthritis Rheumatol. 2014;66(8):2113–2123. doi: 10.1002/art.38644Tedeschi V, Paldino G, Paladini F, Mattorre B, Tuosto L, Sorrentino R, et al. The impact of the 'mis-peptidome' on HLA class I-mediated diseases: Contribution of ERAP1 and ERAP2 and effects on the immune response. Int J Mol Sci. 2020;21(24):9608. doi: 10.3390/ijms21249608Colbert RA, Navid F, Gill T. The role of HLA-B*27 in spondyloarthritis. Best Pract Res Clin Rheumatol. 2017;31(6):797–815. doi: 10.1016/j.berh.2018.07.012Dangoria NS, DeLay ML, Kingsbury DJ, Mear JP, Uchanska-Ziegler B, Ziegler A, et al. HLA-B27 misfolding is associated with aberrant intermolecular disulfide bond formation (dimerization) in the endoplasmic reticulum. J Biol Chem. 2002;277(26):23459–23468. doi: 10.1074/jbc.M110336200Rahmati S, Tsoi L, O'Rielly D, Chandran V, Rahman P. Complexities in Genetics of Psoriatic Arthritis. Curr Rheumatol Rep. 2020;22(4):10. doi: 10.1007/s11926-020-0886-xCaputo V, Strafella C, Termine A, Dattola A, Mazzilli S, Lanna C, et al. Overview of the molecular determinants contributing to the expression of Psoriasis and Psoriatic Arthritis phenotypes. J Cell Mol Med. 2020;24(23):13554–13563. doi: 10.1111/jcmm.15742Patrick MT, Stuart PE, Raja K, Gudjonsson JE, Tejasvi T, Yang J, et al. Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients. Nat Commun. 2018;9(1):4178. doi: 10.1038/s41467-018-06672-6